HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
26 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CHD4
chromodomain helicase DNA binding protein 4
Chromosome 12 Β· 12p13.31
NCBI Gene: 1108Ensembl: ENSG00000111642.16HGNC: HGNC:1919UniProt: A0A2U3TZM0
378PubMed Papers
21Diseases
0Drugs
69Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHomologous RecombinationHub GeneTranscription Factor
RESEARCH IMPACT
Highly StudiedTrendingVariant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
chromatincentrosomechromosome, telomeric regionnucleoplasmSifrim-Hitz-Weiss syndromeneurodegenerative diseasegenetic disorderendometrial cancer
✦AI Summary

CHD4 is an ATP-dependent chr12-remodeling helicase that repositions nucleosomes and distorts nucleosomal DNA to regulate transcription and genome stability 1. As a core component of the histone deacetylase NuRD complex, CHD4 participates in chr12 remodeling and transcriptional repression 2. CHD4 localizes to acetylated damaged chr12 in a ZMYND8-dependent manner and regulates double-strand break repair through homologous recombination by fine-tuning histone acetylation at damage sites 3. In the thymus, CHD4 contributes to promiscuous gene expression necessary for tolerance induction 4. Functionally, CHD4 controls chr12 accessibility and gene expression critical for Ξ²-cell insulin secretion and glucose homeostasis 5. Disease relevance: De novo mutations in CHD4 cause Sifrim-Hitz-Weiss syndrome, a multisystemic neurodevelopmental disorder characterized by global developmental delay, intellectual disability, brain anomalies, congenital heart defects, macrocephaly, hypogonadism, and skeletal anomalies 26. CHD4 variants are significantly enriched in syndromic congenital heart disease patients 7. In cancer, CHD4 overexpression drives gastric cancer metastasis through the MYH9/GSK3Ξ²/Ξ²-catenin axis and epithelial-mesenchymal transition 8. The variant-specific nature of CHD4 mutations results in altered protein function affecting ATP hydrolysis and nucleosome remodeling activities 2.

Sources cited
1
CHD4 is an ATP-dependent chromatin remodeling enzyme that repositions nucleosomes through a central remodeling mechanism shared with other remodelers
PMID: 39221830
2
CHD4 de novo variants cause Sifrim-Hitz-Weiss syndrome with developmental delay, intellectual disability, brain anomalies, congenital heart defects, and dysmorphic features; missense variants alter CHD4 function in ATP hydrolysis and chromatin remodeling
PMID: 31388190
3
CHD4 is released from NEAT1 upon DNA damage to fine-tune histone acetylation at double-strand breaks for genome protection
PMID: 39362776
4
CHD4 is involved in promiscuous gene expression in the thymus for tolerance induction
PMID: 33537838
5
CHD4 controls chromatin accessibility and expression of genes critical for Ξ²-cell insulin secretion and glucose homeostasis
PMID: 36913741
6
CHD4 de novo mutations are genome-wide significantly associated with syndromic congenital heart disease
PMID: 27479907
7
CHD4 is among genes enriched in damaging de novo mutations in developmental disorders
PMID: 28135719
8
CHD4 is overexpressed in gastric cancer and drives metastasis through the MYH9/GSK3Ξ²/Ξ²-catenin axis and epithelial-mesenchymal transition
PMID: 40480417
Disease Associationsβ“˜21
Sifrim-Hitz-Weiss syndromeOpen Targets
0.81Strong
neurodegenerative diseaseOpen Targets
0.55Moderate
genetic disorderOpen Targets
0.50Moderate
endometrial cancerOpen Targets
0.47Moderate
Uterine CarcinosarcomaOpen Targets
0.44Moderate
colon adenocarcinomaOpen Targets
0.40Moderate
syndromic intellectual disabilityOpen Targets
0.37Weak
Endometrial Serous AdenocarcinomaOpen Targets
0.37Weak
Endometrial Endometrioid AdenocarcinomaOpen Targets
0.37Weak
bile duct carcinomaOpen Targets
0.37Weak
colorectal adenocarcinomaOpen Targets
0.37Weak
cutaneous melanomaOpen Targets
0.37Weak
gastric adenocarcinomaOpen Targets
0.37Weak
skin basal cell carcinomaOpen Targets
0.37Weak
head and neck squamous cell carcinomaOpen Targets
0.34Weak
acute lymphoblastic leukemiaOpen Targets
0.33Weak
clear cell renal carcinomaOpen Targets
0.32Weak
acute myeloid leukemiaOpen Targets
0.30Weak
melanomaOpen Targets
0.30Weak
non-small cell lung carcinomaOpen Targets
0.30Weak
Sifrim-Hitz-Weiss syndromeUniProt
Pathogenic Variants69
NM_001273.5(CHD4):c.3280G>A (p.Glu1094Lys)Pathogenic
Sifrim-Hitz-Weiss syndrome|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 1094
NM_001273.5(CHD4):c.2366A>T (p.Asn789Ile)Likely pathogenic
Sifrim-Hitz-Weiss syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 789
NM_001273.5(CHD4):c.2660G>A (p.Arg887Gln)Likely pathogenic
not provided|Sifrim-Hitz-Weiss syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 887
NM_001273.5(CHD4):c.3517C>T (p.Arg1173Trp)Pathogenic
Sifrim-Hitz-Weiss syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 1173
NM_001273.5(CHD4):c.3548G>A (p.Arg1183His)Pathogenic
Sifrim-Hitz-Weiss syndrome|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 1183
NM_001273.5(CHD4):c.4018C>T (p.Arg1340Cys)Pathogenic
Sifrim-Hitz-Weiss syndrome|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 1340
NM_001273.5(CHD4):c.3539T>G (p.Val1180Gly)Likely pathogenic
Sifrim-Hitz-Weiss syndrome
β˜…β˜…β˜†β˜†2024β†’ Residue 1180
NM_001273.5(CHD4):c.3203G>A (p.Arg1068His)Pathogenic
Sifrim-Hitz-Weiss syndrome|Inborn genetic diseases
β˜…β˜…β˜†β˜†2024β†’ Residue 1068
NM_001273.5(CHD4):c.3653T>C (p.Ile1218Thr)Likely pathogenic
Sifrim-Hitz-Weiss syndrome|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 1218
NM_001273.5(CHD4):c.3547C>T (p.Arg1183Cys)Pathogenic
Sifrim-Hitz-Weiss syndrome|Inborn genetic diseases|not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 1183
NM_001273.5(CHD4):c.3530G>A (p.Arg1177His)Pathogenic
not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 1177
NM_001273.5(CHD4):c.3326T>C (p.Ile1109Thr)Pathogenic
not provided|CHD4-related disorder
β˜…β˜…β˜†β˜†2023β†’ Residue 1109
NM_001273.5(CHD4):c.3518G>A (p.Arg1173Gln)Pathogenic
Inborn genetic diseases|not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 1173
NM_001273.5(CHD4):c.3529C>T (p.Arg1177Cys)Pathogenic
Sifrim-Hitz-Weiss syndrome
β˜…β˜…β˜†β˜†2022β†’ Residue 1177
NM_001273.5(CHD4):c.3441C>G (p.Asp1147Glu)Pathogenic
not provided
β˜…β˜†β˜†β˜†2026β†’ Residue 1147
NM_001273.5(CHD4):c.2450G>C (p.Arg817Pro)Likely pathogenic
Sifrim-Hitz-Weiss syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 817
NM_001273.5(CHD4):c.3290A>T (p.Asp1097Val)Likely pathogenic
not provided|Sifrim-Hitz-Weiss syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 1097
NM_001273.5(CHD4):c.2949-1G>ALikely pathogenic
not provided
β˜…β˜†β˜†β˜†2025
NM_001273.5(CHD4):c.4147+2T>ALikely pathogenic
Sifrim-Hitz-Weiss syndrome
β˜…β˜†β˜†β˜†2025
NM_001273.5(CHD4):c.1715G>A (p.Arg572Gln)Likely pathogenic
Sifrim-Hitz-Weiss syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 572
View on ClinVar β†—
Related Genes
RBBP4Protein interaction100%H2AC8Protein interaction100%H3-4Protein interaction100%H3-3BProtein interaction100%BRD4Protein interaction100%H3C13Protein interaction100%
Tissue Expression6 tissues
Brain
100%
Lung
71%
Ovary
70%
Liver
48%
Heart
17%
Bone Marrow
15%
Gene Interaction Network
Click a node to explore
CHD4RBBP4H2AC8H3-4H3-3BBRD4H3C13
PROTEIN STRUCTURE
Preparing viewer…
PDB6Q3M Β· 2.52 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.19Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.14 [0.11–0.19]
RankingsWhere CHD4 stands among ~20K protein-coding genes
  • #800of 20,598
    Most Researched378 Β· top 5%
  • #1,047of 5,498
    Most Pathogenic Variants69 Β· top quartile
  • #405of 17,882
    Most Constrained (LOEUF)0.19 Β· top 5%
Genes detectedCHD4
Sources retrieved26 papers
Response timeβ€”
πŸ“„ Sources
26β–Ό
1
Prevalence and architecture of de novo mutations in developmental disorders.
PMID: 28135719
Nature Β· 2017
1.00
2
Thymus and autoimmunity.
PMID: 33537838
Semin Immunopathol Β· 2021
0.90
3
The CHD4-related syndrome: a comprehensive investigation of the clinical spectrum, genotype-phenotype correlations, and molecular basis.
PMID: 31388190
Genet Med Β· 2020
0.80
4
Galectin-7 Induction by EHMT2 Inhibition Enhances Immunity in Microsatellite Stability Colorectal Cancer.
PMID: 38065340
Gastroenterology Β· 2024
0.72
5
PMID: 32881470
0.70